José-Alain Sahel, M.D., founder and director of the Vision Institute in Paris and currently a professor at the Sorbonne’s medical school Université Pierre-et-Marie-Curie, has joined UPMC
and Pitt’s faculty.
Dr. Sahel is known worldwide for his expertise in vision restoration techniques. He has developed several interventions— including stem cell implantation, gene therapy, innovative pharmacologic approaches and the artificial retina—for retinitis pigmentosa, age-related macular degeneration, vascular eye disease and other vision impairments that currently are untreatable. Over the past decade he has led pioneering efforts in optogenetic vision restoration, a technique in which cells in the retina are genetically modified to express light sensitive proteins. This therapeutic technique has the potential to help patients who are blind or visually impaired as a result of a genetic defect.
He also brings a strong neuroscience perspective to ophthalmology research, such as exploring the application of brain-computer interface technology, for which Pitt and UPMC are well known.
“We are delighted that Dr. Sahel has chosen to bring his remarkable talent to UPMC where he will, with immediacy, translate laboratory advances into treatment for patients with visual impairment,” said Steve Shapiro, M.D., chief medical and scientific officer at UPMC. “His creativity and commitment to bringing everything from rigorous basic science to eyesight-saving surgery to patient care are unparalleled. With his leadership, we expect to build on the amazing accomplishments he already has achieved in Paris as well as break new ground in vision research and care.”
“Dr. Sahel is a gifted physician-scientist with a heartfelt dedication to his patients and a broad intellectual reach. His work will soon have great impact on the ophthalmology department, on bench-to-bedside treatments for patients, and also on Pitt as a whole,” said Arthur S. Levine, M.D.
, Pitt’s senior vice chancellor for the health sciences and John and Gertrude Petersen Dean of Medicine.
Dr. Sahel will sustain his engagement with the Vision Institute, one of the world’s largest centers of integrated research on eye diseases, through a partnership formed between the Institute, the Sorbonne, Pitt School of Medicine and UPMC.
“I am very impressed with the strong support and energy at UPMC and Pitt, and share their objectives of developing creative new treatments and diagnostic tools to better serve patients,” Dr. Sahel said. “It was clear to me during my visits that the community is warm and welcoming, and rightfully proud of its city. I look forward to contributing to these impressive academic and health care legacies.”
As director of UPMC Vision Institute, which is rated among the top ophthalmology programs in the United States in the delivery of care, Dr. Sahel will see patients, particularly those with complex diseases, and will lead UPMC clinicians in the diagnosis and treatment of both common and unusual eye disorders. The UPMC Vision Institute is home to an outstanding ophthalmology teaching program that trains residents and clinical fellows in their pursuit of clinical, research and clinician-scientist careers.
Dr. Sahel is a co-inventor on more than 40 patents, several of which have led to start-up companies including Fovéa Inc., which Dr. Sahel founded and later became the Ophthalmologic Division of Sanofi Aventis. He also is a scientific co-founder of GenSight Biologics Inc. and Pixium Vision Inc. He is a member of 11 editorial boards, including the Journal of Clinical Investigation and Science Translational Medicine.
He also holds the positions of Cumberlege Professor of Biomedical Sciences at the Institute of Ophthalmology, University College London, and chairman of the Departments of Ophthalmology at the Quinze-Vingts National Eye Hospital and at the Rothschild Ophthalmology Foundation, both in Paris. At the Paris-based Ophthalmology Clinical Investigation Center, he oversees more than 50 clinical trials, many of which are focused on retinal implants, gene therapy and other advanced biomedical technologies. He also heads the French National Reference Center for Retinal Dystrophies and chairs a network of more than 90 European clinical trial centers focused on retinal diseases.
He has been the recipient of numerous honors and awards, which include membership in the Legion of Honour (2008); the National Order of Merit (2002) and induction into the Collège de France, the highest honor awarded to a French scientist. He is an elected member of the Académie des sciences-Institut de France, the Académie des technologies, the Academia Ophthalmologia Internationalis and the German National Academy of Sciences. He has also received the Grand Prix for Neurosciences of the Foundation NRJ, Institut de France; the CNRS Medal of Innovation; the Foundation for Fighting Blindness Trustee Award and the Liura Liggett-Gund Award, among others. Dr. Sahel holds an honorary degree from the University of Geneva.
Dr. Sahel, who was born in Algeria, studied medicine at Strasbourg University and in Lariboisière, Saint-Louis. He received his medical degree with a Medal of the Faculty of Paris and obtained his specialty certification in ophthalmology. He completed a residency in neurology and neurosurgery at the Louis Pasteur University Hospital in Strasbourg. He also was a research fellow at the Massachusetts Eye and Ear Infirmary and a visiting scholar in the Department of Molecular and Cellular Biology at Harvard University.